Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine

Drug Development Research

Volumn 47, Issue 3, 1999, Pages 127-136

  Terry Jr , Alvin V ^a,b   Buccafusco, J J ^a,b   Prendergast, M A ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Desensitization; Learning; Memory; Nicotine; Receptor blockade

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MECAMYLAMINE; RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; LEARNING; MACACA; MALE; MAZE TEST; MEMORY; NONHUMAN; RAT; TASK PERFORMANCE;

EID: 0344603807     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2299(199907)47:3<127::aid-ddr3>3.0.co;2-%23     Document Type: Article

References (76)

1. Abdulla FA, Bradbury E, Calaminici MR, Lippiello PM, Wonnacott S, Gray JA, Sinden JD. 1996. Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation. Psychopharmacology 124:323-331.
2. 3H]nicotine to rat brain membanes. FEBS Lett 157:147-149.
3. 3H]Mecamylamine binding to rat brain membranes: studies with mecamylamine and nicotine analogues. Biochem Pharmacol 40:2105-2110.
4. Bannon AW, Decker MW, Williams M, Arneric SP. 1995. Psychotherapeutic potential of selective neuronal nicotinic acetylcholine receptor ligands. In: Domino EF, editor. Brain imaging of nicotine and tobacco smoking. Ann Arbor, MI: NPP Books. p 311-334.
5. Beach JW, Damaj MI, Jonnala RR, Terry AV Jr, Buccafusco JJ. 1998. Synthesis and in vivo and in vitro evaluation of isoarecolone and derivatives. Med Chem Res 8:510-522.
6. Buccafusco JJ, Brezenoff HE. 1980. Opposing influences on behavior mediated by muscarinic and nicotinic receptors in the rat posterior hypothalamic nucleus. Psychopharmacology 67:249-254.
7. Buccafusco JJ, Jackson WJ. 1991. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12:233-238.
8. Buccafusco JJ, Jackson WJ, Terry AV Jr, Marsh KG, Decker MW, Arneric SP. 1995. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology 120:256-266.
9. Cachelin AB, Rust G. 1995. B-Subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflugers Arch Eur J Physiol 429:449-451.
10. 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280:346-356.
11. Clarke PBS, Chaudieu I, el-Bizri H, Boksa P, Quik M, Esplin BA, Capek R. 1994. The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion. Br J Pharmacol 111:397-405.
12. Clarke PBS, Reuben M. 1996. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. Br J Pharmacol 117:607-610.
13. Collins AC, Miner LL, Marks MJ. 1988. Genetic influences on acute responses to nicotine and nicotine tolerance in the mouse. Pharmacol Biochem Behav 30:269-278.
14. Collins AC, Romm E, Wehner JM. 1990. Dissociation of the apparent relationship between nicotine tolerance and up-regulation of nicotinic receptors. Brain Res Bull 25:373-379.
15. Daly JW, Nishizawa Y, Edwards MW, Waters JA, Aronstam RS. 1991. Nicotinic receptor-elicited sodium flux in rat pheochromocytoma PC12 cells: effects of agonists, antagonists, and noncompetitive blockers. Neurochem Res 16:489-500.
16. Damaj MI, Welch SP, Martin BR. 1996. Characterization and modulation of acute tolerance to nicotine in mice. J Pharmacol Exp Ther 277:454-461.
17. Damaj MI, Fei-Yin M, Dukat M, Glassco W, Glennon RA, Martin BR. 1998. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther 284:1058-1065.
18. Decker MW, Majchrzak MJ. 1992. Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats. Psychopharmacology 107:530-534.
19. Decsi L, Karmos-Varszegi M. 1969. Fear and escape reaction evoked by the intrahypothalamic injection of d-tubocurarine in unrestrained cats. Acta Physiol Acad Sci Hung 36:95-104.
20. El-Bizri H, Clarke PB. 1994. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro. Br J Pharmacol 111:406-413.
21. Elrod K, Buccafusco JJ. 1991. Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther 258:403-409.
22. Elrod K, Buccafusco JJ, Jackson WJ. 1988. Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43:277-287.
23. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 47:1948-1954.
24. Freund RK, Jungschaffer DA, Collins AC. 1990. Nicotine effects in mouse hippocampus are blocked by mecamylamine, but not other nicotinic antagonists. Brain Res 511:187-191.
25. Giacobini E, DeSarno P, Clark B, McIlhany M. 1989. The cholinergic receptor system of the human brain. Neurochemical and pharmacological aspects of aging and Alzheimer's. In: Nordberg A, editor. Progress in brain research. Amsterdam: Elsevier. p 335-343.
26. Gitelman DR, Prohovnik I. 1992. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging 13(2):313-318.
27. 3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem 59:848-856.
28. Granon S, Poucet B, Thinus-Blanc C, Changeux JP, Vidal C. 1995. Nicotinic and muscarinic receptors in the rat prefrontal cortex: differential roles in working memory, response selection and effortful processing. Psychopharmacology 119:139-144.
29. Gray JA, Mitchell SN, Joseph MH, Grigoryan GA, Dawe S, Hodges H. 1994. Neurochemical mechanisms mediating the behavioral and cognitive effects of nicotine. Drug Dev Res 31:3-17.
30. Hussy N, Ballivet M, Bertrand D. 1994. Agonist and antagonist effects of nicotine on chick neuronal nicotinic receptors are defined by alpha-subunits and beta subunits. J Neurophysiol 72:1317-1326.
31. James JR, Villanueva HF, Johnson JH, Arezo S, Rosecrans JA. 1994. Evidence that nicotine can acutely desensitize central nicotinic acetylcholinergic receptors. Psychopharmacology 114:456-462.
32. Levin ED. 1992. Nicotinic systems and cognitive function. Psychopharmacology 108:417-531.
33. Levin ED, Rose JE. 1990. Anticholinergic sensitivity following chronic nicotine administration as measured by radial-arm maze performance in rats. Behav Pharmacol 1:511-520.
34. Levin ED, Simon BB. 1998. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217-230.
35. Levin ED, Torry D. 1996. Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology 123:88-97.
36. Levin ED, Briggs SJ, Christopher NC, Rose JE. 1992. Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol 58:152-158.
37. Levin ED, Briggs SJ, Christopher NC, Rose JE. 1993. Chronic nicotinic stimulation and blockade effects on working memory. Behav Pharmacol 4:179-182.
38. Levin ED, Christopher NC, Briggs SJ. 1997a. Chronic nicotinic agonist and antagonist effects on T-maze alternation. Physiol Behav 61:863-866.
39. Levin ED, Kaplan S, Boardman A. 1997b. Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behav Pharmacol 8:236-242.
40. MacLeod NK, James TA, Starr MS. 1984. Muscarinic action of acetylcholine in the rat ventromedial thalamic nucleus. Exp Brain Res 55:553-561.
41. Marks MJ, Collins AC. 1982. Characterization of nicotine binding in mouse brain and comparison with the binding of bungarotoxin and quinuclidinyl benzilate. Mol Pharmacol 22:554-564.
42. Marks MJ, Stitzel JA, Wehner JM, Collins AC. 1986. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine and alpha-bungarotoxin. Mol Pharmacol 30:427-436.
43. Moran PM. 1993. Differential effects of scopolamine and mecamylamine on working and reference memory in the rat. Pharmacol Biochem Behav 45:533-538.
44. Morris RGM. 1984. Development of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
45. Newhouse PA, Potter A, Corwin J, Lenox R. 1992. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 108:480-484.
46. Newhouse PA, Potter A, Corwin J, Lenox R. 1994. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10:93-107.
47. Newhouse PA, Potter A, Levin ED. 1997. Nicotinic system involvement in Alzheimer's and Parkinson's disease. Drugs Aging 11:206-228.
48. O'Dell TJ, Christensen BN. 1988. Mecamylamine is a selective non-competitive antagonist of n-methyl-d-aspartate and aspartate-induced currents in horizontal cells dissociated from catfish retina. Neurosci Lett 94:93-98.
49. Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairbairn A, Blessed G. 1987. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 50:806-809.
50. Pickworth WB, Herning RI, Henningfield JE. 1988. Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. Pharmacol Biochem Behav 30:149-153.
51. Prendergast MA, Buccafusco JJ, Terry AV Jr. 1997. Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion. Pharmacol Biochem Behav 57:347-352.
52. Prendergast MA, Jackson WJ, Terry AV Jr, Kille N, Arneric SP, Decker MW, Buccafusco JJ. 1998a. Age-related differences in distractibility and response to methylphenidate in monkeys. Cerebral Cortex 8:164-172.
53. Prendergast MA, Terry AV Jr, Buccafusco JJ. 1998b. Effects of chronic, low-level organophosphate exposure on delayed recall, discrimination, and spatial learning in monkeys and rats. Neurotoxicol Teratol 20:115-122.
54. 3H]dopamine release from striatal synaptosomes: pharmacological characterization. J Neurochem 54:937-945.
55. Riekkinen P, Riekkinen M, Sirvio J, Riekkinen P. 1992. Effects of concurrent nicotinic antagonist and PCPA treatments on spatial and passive avoidance learning. Brain Res 575:247-250.
56. Riekkinen M, Tolonen R, Riekkinen P. 1994. Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior. Brain Res 649:174-180.
57. Ropert N, Krnjevic K. 1982. Pharmacological characteristics of facilitation of hippocampal population spikes by cholinomimetics. Neuroscience 7:1963-1977.
58. Rowell PP, Wonnacott S. 1990. Evidence for functional activity of up-regulated nicotine binding sites in rat striatal synaptosomes. J Neurochem 55:2105-2110.
59. Rowell PP, Duggan DS. 1998. Long-lasting inactivation of nicotinic receptor function in vitro by treatment with high concentrations of nicotine. Neuropharmacology 37:103-111.
60. Rozental R, Aracava GT, Scoble KL, Swanson S, Wonnacott S, Albuquerque E. 1989. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine. J Pharmacol Exp Ther 251:395-404.
61. Ruotsalainen S, Macdonald E, Miettinen R, Puumala T, Riekkinen P, Sirvio J. 1997. Additive deficits in the choice accuracy of rats in the delayed nonmatching to position task after cholinolytics and serotonergic lesions are non-mnemonic in nature. Psychopharmacology 130:303-312.
62. 3H]nicotine binding to mouse brain homogenate. J Pharm Pharmacol 40:793-797.
63. Stolerman IP, Pratt JA, Garcha HS, Giardini V, Kumar R. 1983. Nicotine cue in rats analyzed with drugs acting cholinergic and 5-hydroxytryptamine mechanisms. Neuropharmacology 22:1029-1037.
64. Terry AV Jr, Clarke MSF. 1994. Nicotine stimulation of nerve growth factor receptor expression. Life Sci 55:PL91-98.
65. Terry AV Jr, Jackson WJ, Buccafusco JJ. 1993. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb Cortex 3:304-312.
66. Terry AV Jr, Buccafusco JJ, Jackson WJ, Zagrodnik S, Evans-Martin FF, Decker MW. 1996. Effects of stimulation or blockade of central nicotinic-cholinergic receptors on performance of a novel version of the rat stimulus discrimination task. Psychopharmacology 123:172-181.
67. Terry AV Jr, Buccafusco JJ, Decker MW. 1997. Cholinergic channel activator, ABT-418 enhances delayed response accuracy in rats. Drug Dev Res 40:304-312.
68. Terry AV Jr, Buccafusco JJ, Prendergast MA, Jackson WJ, Fontana DL, Wong EHF, Whiting RL, Eglen RM. 1998a. The 5-HT4 receptor agonist, RS-17017, enhances delayed matching performance in younger and older macaques. Psychopharmacology 135:407-415.
69. Terry AV Jr, Williamson R, Gattu M, Beach JW, McCurdy CR, Sparks JA, Pauly JR. 1998b. Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology 37:93-102.
70. Van Rossum M. 1962. Classification and molecular pharmacology of ganglionic blocking agents. Part II. Mode of action of competitive and noncompetitive ganglionic blocking agents. Int J Neuropharmacol 1:403-421.
71. Van Rossum JM, Ariëns EJ. 1959. Pharmacodynamics of drugs affecting the blood pressure. Structure-action relationships of quaternary ganglionic and parasympathetic drugs. Arch Int Pharmacodyn Ther 118:447-466.
72. Varanda WA, Aracava Y, Sherby SM, van Meter WG, Eldefrawi ME, Albuquerque EX. 1985, The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol Pharmacol 28:128-137.
73. Westfall TC, Mereu G, Vickery L, Perry H, Naes L, Yoon KP. 1989. Regulation by nicotine of midbrain dopamine neurons. Prog Brain Res 79:173-185.
74. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein P, Coyle JT, Price DL, Kellar KJ. 1986. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371:146-151.
75. Woodruff-Pak DS, Hinchliffe RM. 1997. Mecamylamine-or scopolamine-induced learning impairment: ameliorated by nefiracetam. Psychopharmacology 131:130-139.
76. Yang XH, Buccafusco JJ. 1994. Comparison of the ability of direct and indirect-acting nicotinic agonists to induce nicotinic receptor up-regulation in rat cerebral cortex. Drug Dev Res 31:95-101.